Source-grounded facts extracted from Avalo Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Garry A. Neil was appointed as President and Chief Executive Officer at Avalo Therapeutics, Inc..
“On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.”
H. Jeffrey Wilkins resigned as Chief Medical Officer at Avalo Therapeutics, Inc..
“On February 2, 2022, H. Jeffrey Wilkins resigned as Chief Medical Officer of Avalo Therapeutics, Inc., to be effective upon a date to be agreed upon.”
Philip Gutry resigned as Director at Avalo Therapeutics, Inc..
“As previously reported, pursuant to the Agreement, Mr. Philip Gutry’s resignation from the Board became effective on the date of Mr. Chan’s appointment to the Board.”
Mitchell Chan was appointed as Director at Avalo Therapeutics, Inc..
“On December 1, 2021, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Mitchell Chan, to the Board, effective immediately, pursuant to the terms of that certain Cooperation Agreement, dated as of November 4, 2021, with Armistice Capital, LLC (“ Agreement ”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.